These authors claimed that the combined effect on amyloid β1–42 and tau phosphorylation represented a multitarget therapeutic approach for AD, which might be more effective for this multifactorial and complex neurodegenerative disease than the current treatments. The gene discussed is MAPT; the disease is neurodegenerative disease.